Brief: EyeGate Pharma Completes Target Enrollment In Phase 2 Proof-Of-Concept Study To Evaluate PP-001 For Treatment Of Ocular Surface Inflammation

Kiora Pharmaceuticals

08/09/2021 12:03

Sept 8 (Reuters) - EyeGate Pharmaceuticals Inc  EYEG.O :
    * EYEGATE PHARMA COMPLETES TARGET ENROLLMENT IN PHASE 2
PROOF-OF-CONCEPT STUDY TO EVALUATE PP-001 FOR THE TREATMENT OF
OCULAR SURFACE INFLAMMATION
    * EYEGATE PHARMACEUTICALS - TRIAL REMAINS ON TRACK WITH
TOPLINE
DATA EXPECTED IN Q4 2021

Source text for Eikon:  ID:nGNX7Lzb90 
Further company coverage:  EYEG.O 

 ((Reuters.Briefs@thomsonreuters.com;))